Search

Merck, a leading science and technology company, today announced new real-world data from the MSBase Registry demonstrating MAVENCLAD (cladribine tablets) had more favourable relapse outcomes and longer time to switch [...]

Germany, Feb. 25 -- New real-world data show MAVENCLAD(R) (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate [...]

ENPNewswire-February 25, 2022--EMD Serono - New MAVENCLAD Data at ACTRIMS Forum 2022 Show Favorable Efficacy Outcomes Versus Other Oral DMTs and Lower Occurrence of Further Relapses or Disability Progression (C)2022 [...]

Germany: Merck KGaA has issued the following press release: New real-world data show MAVENCLAD(r) (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to [...]

* New real-world data show MAVENCLAD([R]) (cladribine) tablets had lower annualized relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide in [...]

ENPNewswire-January 17, 2022--EMA - Meeting highlights from the Pharmacovigilance Risk Assessment Committee (C)2022 ENPublishing - http://www.enpublishing.co.uk Release date- 14012022 - Review of terlipressin medicines started EMA has started a review [...]

EXTON: Spherix Global Insights has issued the following news release: 2021 delivered a number of impactful changes to the multiple sclerosis (MS) market in Canada, including: Novartis' Kesimpta was approved [...]

The negative CDEC reimbursement recommendation for BMS' Zeposia highlights the risk (or opportunity) for Janssen's Ponvory launch, while the advent of generic dimethyl fumarate could dampen uptake of Biogen's Vumerity [...]

Merck today announced new interim real-world data on MAVENCLAD (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experienced a significant improvement in quality-of-life (QoL) scores after the first [...]

ROCKLAND, Mass.: EMD Serono has issued the following news release: EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced new interim [...]

ENPNewswire-October 14, 2021--EMD Serono, Inc. - New Real-World MAVENCLAD Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 13102021 - ROCKLAND, [...]

On 13 Oct 2021, Merck announced new interim real-world data on MAVENCLAD (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experienced a significant improvement in quality-of-life (QoL) scores after the first course of treatment in Year 1 with MAVENCLAD. Additionally, late-breaking real-world MAVENCLAD data evaluating long-term mobility and disability status suggested sustained benefit beyond the last treatment course and a reduced need for a wheelchair or ambulatory device among MAVENCLAD-treated patients. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). A new interim analysis from the open-label Phase IV CLARIFY-MS study demonstrated improvements in QoL measures in 426 patients with RMS early in the treatment course (Year 1). After completing half the recommended cumulative dose of MAVENCLAD over two years, improvements from baseline were observed for physical and mental health composite scores (nominal p less than 0.0001) as measured by the Quality of Life-54 questionnaire. Safety data were consistent with the safety profile seen in the MAVENCLAD clinical development programme. Also presented were late-breaking final data from the Phase IV CLASSIC-MS, a follow-up study, which showed that 90.0% of patients with RMS treated with cladribine tablets did not need to use a wheelchair or were not confined to bed (ie, with an Expanded Disability Status Scale less than 7) after a median follow-up of 10.9 years (range 9.3-14.9). Additionally, 81.2% of cladribine tablets-treated patients did not require an ambulatory device. CLASSIC-MS investigated the long-term efficacy in 435 patients with RMS - 90.6% of whom were exposed to cladribine tablets during the CLARITY and CLARITY Extension trials. The study focused on long-term mobility and disability - two areas of importance as MS can cause problems with movement, balance and coordination that can worsen over time. An independent study, presented by Prof Adi Vaknin-Dembinsky, MD, PhD, Senior Neurologist, Hadassah Medical Center at the Hebrew University, Jerusalem, Israel, evaluated antibody response after a complete course of the Pfizer/BioNTech mRNA COVID-19 vaccine in healthy controls and patients with MS (untreated, or treated with MAVENCLAD or interferon beta-1a). Consistent with previously reported data, MAVENCLAD-treated patients, as well as those treated with interferon beta-1a, who received the Pfizer/BioNTech mRNA COVID-19 vaccine were found to mount a positive serology response (AU/mL more than 19), similar to that of healthy controls. Specifically, all patients with MS treated with MAVENCLAD (n=30) had a positive serology response against the spike protein two to three weeks after vaccination (mean=226.3 plus-minus 121.4). In the study, the shortest interval between vaccination and the last dose of MAVENCLAD was 12 weeks. Original source: Merck KGaA, website: https://www.merckgroup.com/en, Copyright Merck KGaA 2021., research and development; antiviral vaccines; beta-1a interferon; cladribine; MAVENCLAD; messenger RNA; BioNTech; Merck; [...]

* New data presented at ECTRIMS 2021 highlight improvement in measures of physical and mental health of patients with relapsing multiple sclerosis (RMS) after one year of treatment with MAVENCLAD([R]) [...]

ENPNewswire-October 5, 2021--EMD Serono Completes Enrollment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021 (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 04102021 - ROCKLAND, Mass - EMD Serono, the [...]

DUBLIN: Research and Markets has issued the following news release: The 'Multiple Sclerosis: Update Bulletin' newsletter has been added to ResearchAndMarkets.com's offering. This report presents key opinion leader (KOL) views [...]

DUBLIN -- The 'Multiple Sclerosis: Update Bulletin' newsletter has been added to ResearchAndMarkets.com's offering. This report presents key opinion leader (KOL) views on recent developments in the multiple sclerosis (MS) [...]

M2 PRESSWIRE-July 14, 2021-: 2021 Update Bulletin on Multiple Sclerosis - Ocrevus Has Been Approved by the European Commission (C)1994-2021 M2 COMMUNICATIONS RDATE:14072021 The 'Multiple Sclerosis: Update Bulletin' newsletter has [...]

Contract notice: Delivery of medicines - Mavenclad - L04AA40 Major organization : FAKULTN THOMAYEROVA NEMOCNICE (00064190) Address : Postal Address: Vdensk 800 Town: Praha 4 Postal Code: 140 00 Czechia [...]

Contract award notice:Discount agreement according to Section 130 c (1) SGB V between IKK classic and Merck Serono GmbH for Mavenclad (R) Contractor name : MERCK SERONO GMBH Contractor address [...]

Belen Garijo took over last month as CEO at Merck KGaA and shes not wasting time putting her imprint on the company. On Tuesday, the Germany-based company said it had [...]

Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated [...]

Germany, April 26 -- New analysis indicates a specific immune repopulation pattern in people treated with MAVENCLAD, which may contribute to their ability to fight infections and develop protective antibodies [...]

ENPNewswire-April 26, 2021--Merck Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD Use During the COVID-19 Pandemic (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 23010420 - 042021 Darmstadt, Germany [...]

ENPNewswire-April 26, 2021--EMD Serono - New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD Use During the COVID-19 Pandemic (C)2021 ENPublishing - http://www.enpublishing.co.uk Release date- 23042021 - ROCKLAND - [...]

ROCKLAND: EMD SERONO has issued the following news release: EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the [...]

Germany: Merck KGaA has issued the following press release: Merck, a leading science and technology company, today announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation [...]

Germany: Merck KGaA has issued the following press release: Sales increase by 8.6% to EU 17.5 billion; EBITDA pre jumps 18.6% to EU 5.2 billion; EBITDA pre margin rises to [...]

Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD (cladribine tablets) in patients with relapsing multiple sclerosis (RMS) [...]

Germany: Merck KGaA has issued the following press release: Merck, a leading science and technology company, today announced the presentation of a new analysis from the MAGNIFY-MS study on MAVENCLAD(r) [...]

- MAGNIFY-MS retrospective analysis demonstrates patients develop protective antibody levels for at least six months following seasonal influenza and varicella zoster vaccines, irrespective of vaccine timing relative to MAVENCLAD dosing [...]

- Crystal is a wife, mother of four and a frontline healthcare worker who also happens to have multiple sclerosis . Though she had experienced numbness, tingling and pain since [...]

- Crystal is a wife, mother of four and a frontline healthcare worker who also happens to have multiple sclerosis . Though she had experienced numbness, tingling and pain since [...]

- Crystal is a wife, mother of four and a frontline healthcare worker who also happens to have multiple sclerosis . Though she had experienced numbness, tingling and pain since [...]

The MS Society in the UK has announced that recruitment of patients will start next year in the multiple sclerosis (MS) trial focused only on people who cannot walk. The [...]

Germany: Merck KGaA has issued the following press release: Group net sales increase organically by 7.2%; EBITDA pre up 19.8% organically, excluding release of the provision for patent dispute with [...]

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, is pleased to announce that eligible patients have access to PrMAVENCLAD (cladribine tablets) through seven [...]

Germany: Merck KGaA has issued the following press release: In MAGNIFY-MS, patients experienced a rapid onset of action from end of month 1 that was significant in all study periods [...]

ENPNewswire-September 4, 2020--EMD Serono to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 03092020 - ROCKLAND - EMD Serono, the [...]

Germany: Merck KGaA has issued the following press release: Company to present 54 abstracts across its MS portfolio - MAVENCLAD(r) (cladribine tablets), Rebif(r) (interferon beta-1a) and investigational evobrutinib New long-term [...]

- Company to present 54 abstracts across its MS portfolio - MAVENCLAD (cladribine) tablets, Rebif (interferon beta-1a) and investigational evobrutinib - New data and real-world evidence further characterize the efficacy [...]

Contract brings guaranteed value to payers, aims to improve patient experience EAGAN, Minn., June 8, 2020 /PRNewswire/ -- Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving more [...]

EXTON: Spherix Global Insights has issued the following press release: In the last year, the US multiple sclerosis (MS) market saw the introduction of three new disease-modifying therapies (DMTs) for [...]